Rosemont Pharmaceuticals chooses Certero AssetStudio™ to improve their SAM capability

01 October 2010

Rosemont Pharmaceuticals Ltd has chosen Certero AssetStudio™ as a key part of their programme to implement best of breed Software Asset Management solution. James Taylor, IT Officer says, “AssetStudio™ was recommended to us and I am pleased that we followed up the recommendation. Certero have some excellent products and AssetStudio™ has helped us enormously. Certero’s evaluation process enabled us come to a decision to purchase in a speedy manner and given that this assistance was free; this removed any risk on our part”.

Rosemont Pharmaceuticals Ltd. is a leading developer, manufacturer and supplier of high quality oral liquid medicines which are used by patients who are unable or unwilling to swallow solid medications. They are based in Leeds, West Yorkshire in the UK, and employ approximately 210 people. Through our significant R&D expertise, we have developed over 100 oral liquid medicines, and our customers see us as 'The Source of Liquid Solutions'.

John Lunt, managing director and co-founder of Certero, says, “We are excited that Certero’s reputation is being recognised in such a positive manner. At Certero we endeavour to provide the very best to our customers with great products and services and we are happy that this is being recognised through our customer recommendations’